Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Phase 2/3 Completed 394 enrolled AB Science

RandomizedParallel-groupDouble-blindTreatment

Summary

The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).

Timeline

Start: 2013-04
Primary completion: 2016-12-05
Completion: 2018-03

Publications

Mora JS, Bradley WG, Chaverri D, Hernandez-Barral M, Mascias J, Gamez J, Gargiulo-Monachelli GM, Moussy A, Mansfield CD, Hermine O, Ludolph AC. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2021 Jul 19;14:17562864211030365. doi: 10.1177/17562864211030365. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Masitinib	Small molecule	3 mg/kg	Oral
Subject	Masitinib	Small molecule	4.5 mg/kg	Oral
Background	Riluzole	Small molecule	—	—

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Summary

Timeline

Publications

Drugs

Indications